Le Lézard
Classified in: Health
Subject: TRI

Centerline Biomedical Completes Fifth Preclinical Study

CLEVELAND, Jan. 4, 2018 /PRNewswire/ -- As Centerline Biomedical, Inc. prepares to meet with investors, strategic partners and companies in the healthcare industry during the JP Morgan Healthcare Conference, it successfully completed a fifth preclinical study at Cleveland Clinic facilities evaluating its surgical navigation system, IOPS, the Intra-Operative Positioning System. This study was the most noteworthy Centerline study to date, demonstrating ability to track sensorized IOPS instruments precisely and efficiently, with enhanced 3-D visualization, without frequent exposure to cancer-causing ionizing radiation associated with current standard of care. Endovascular surgeries i.e. those which repair arteries using stents rely on X-ray fluoroscopy, which provides limited two-dimensional visualization, leading to long procedure times while exposing surgeons and patients to damaging radiation. IOPS, originally developed at Cleveland Clinic, uses a 3-D model of a patient's vascular system to track instruments precisely without ionizing radiation, with the goal of reducing procedure times, complication rates, and overall costs. The mathematical algorithms used to generate the 3-D model are currently being used to revolutionize minimally invasive surgery, with future applications in surgical training and clinical decision support.

Navigation of catheter and guidewire through vasculature using IOPS

The study was led by Dr. Matthew Eagleton, Chief of Massachusetts General Hospital's Division of Vascular and Endovascular Surgery. An international thought leader on minimally-invasive aortic repair, Dr. Eagleton also serves as co-director of the Fireman Vascular Center and Thoracic Aorta Center at Massachusetts General, as well as chairing Centerline's Scientific Advisory Board; and Dr. Ezequiel Parodi, vascular surgeon and endovascular specialist at the Cleveland Clinic's Miller Heart & Vascular Institute and Scientific Advisor to Centerline, with associated financial interest in the company.

Dr. Parodi used Centerline's system for the first time in this study and noted the significant visualization and workflow advantages afforded by IOPS, commenting, "I observed a high level view of vasculature along with a more magnified, localized view. I don't have to constantly change views to highlight areas of interest." Dr. Eagleton, who used the system previously, took note of the rapid progress achieved and ease of adoption, remarking, "I am impressed by the rapid advancement of Centerline's platform technology as evidenced by the results of this preclinical study. I see surgeons and administrators being able to quickly adapt this technology within their own facilities." 

Centerline, a Cleveland Clinic spinoff company founded in 2014, is a joint venture of G2 Group Ventures and Cleveland Clinic. This fifth preclinical study allows Centerline to visualize how the IOPS technology will function once entering the market, while offering confidence in the seamless integration into current workflow. Centerline's technical work is validated and bolstered by the successful raising of $12.7M of funding to date. Centerline Chairman and CEO Dr. Jai Gupta was delighted by the results of the study, stating, "This milestone study bolstered the view that IOPS is a novel technology that will disrupt the market, offering surgeons and the endovascular community something they've never seen before."

Endovascular Navigation Innovator Centerline Biomedical Successfully Completes First Preclinical Study
In vivo study bolsters commercialization efforts

SOURCE Centerline Biomedical

These press releases may also interest you

at 08:01
MegaFood®, an award-winning dietary supplement brand whose products are made with real, whole foods, was named winner of the New Hope Network 2018 Expo West NEXTY Award for outstanding new products in the natural products industry. MegaFood's newly...

at 08:00
U.S. Food and Drug Administration (FDA) approves label change for UCB's CIMZIA® (certolizumab pegol) Data added to the label includes first-of-their-kind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and...

at 08:00
Cardiome Pharma Corp. , a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, announced today that Health Canada has accepted its New Drug Submission (NDS) for review of Xydalbatm...

at 08:00
The Industry growth report "Reprocessed Medical Devices Market Size By Product (Cardiovascular Medical Devices {Blood Pressure Cuffs/Tourniquet Cuffs, Electrophysiology Cables, Cardiac Stabilization and Positioning Devices, Diagnostic...

at 08:00
Phivida Holdings Inc. ("Phivida" or the "Company") is pleased to report the signing of a Letter of Intent (LOI) with Athletes for Care, Inc. (A4C). Terms of the LOI pertain to a prospective partnership in cannabinoid education and research with...

at 08:00
HIMSS Analytics® today announced the expansion of the LOGICtm health IT market intelligence platform to include Predict, a new solution to help sales and marketing teams understand their clients' propensity to purchase health IT solutions. LOGIC...

News published on 4 january 2018 at 08:00 and distributed by: